Sells biologic matrix products for soft-tissue reconstruction and cardiovascular repair to healthcare facilities, and develops drug-eluting biomatrix products for reconstructive surgery.
10-K for FY2025, filed Mar 13, 2026At Elutia, our mission is to humanize medicine so that patients can thrive without compromise. We develop proprietary drug-eluting…View ↗
Following the sale of the CIED business, we are focused on advancing our drug-eluting biomatrix (“DEB”) platform. This platform builds on…View ↗
Elutia continues to market and sell its proprietary biologic matrix products, including SimpliDerm, a human acellular dermal matrix…View ↗
Women’s Health was 74% of revenue; healthcare facilities buy SimpliDerm, with sales earning revenue when products ship or are delivered, or when consigned stock is used or implanted.
10-K for FY2025, filed Mar 13, 2026SimpliDerm is an hADM marketed for use in soft tissue repair, reinforcement, and reconstruction. It is manufactured using a proprietary…View ↗
As noted above, the Company enters into contracts to primarily sell and distribute products to healthcare providers. Revenue is recognized…View ↗
A portion of the Company’s product revenue is generated from consigned inventory maintained at hospitals and from inventory physically held…View ↗
10-K for FY2025, filed Mar 13, 2026
FY2025 revenue by reportable segment ↗$12.3M
10-K for FY2025, filed Mar 13, 2026
$12.3M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Women's Health
Sold outright
10-K for FY2025, filed Mar 13, 2026 |
74% |
Women's Health, FY2025
$9.1M Sources
|
Sold outright |
|
Cardiovascular
Sold outright
10-K for FY2025, filed Mar 13, 2026 |
26% |
Cardiovascular, FY2025
$3.2M Sources
|
Sold outright |
SimpliDerm is sold to plastic and reconstructive surgeons through independent sales agents; cardiovascular products go to hospitals and other healthcare facilities through independent sales agents.
10-K for FY2025, filed Mar 13, 2026
10-K for FY2025, filed Mar 13, 2026
During the year ended December 31, 2025, there was one customer that represented 18% of the Company’s net sales in such year, and during…View ↗
Yes. Its net income in FY2025 was larger than its revenue, but spent more cash than it brought in: free cash flow was −$46.7M.
10-Q for Q3 FY2026, filed Nov 10, 2026
−$1.3MView ↗
8-K, filed Aug 21, 2026
On August 17, 2026, the parties completed the sale of the SimpliDerm Business. In accordance with the Purchase Agreement, $7.7 million of…View ↗
8-K, filed Aug 7, 2026
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a compliance period of 180 calendar days from the date of…View ↗
Shrinking. Revenue fell 74% in 4 years, from $47.4M in FY2021 to $12.3M in FY2025, about 29% a year.
Narrower product portfolio
The earlier report described products across device protection, women’s health, orthobiologics and cardiovascular markets. The latest report describes a focus on drug-eluting biomatrix development, alongside commercial products for reconstructive and cardiovascular repair.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 13, 2026Our products are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications…View ↗
Reconstructive development focus
The earlier report planned an antibacterial device-protection pouch and candidates for device protection, women’s health and orthobiologics; the latest centers development on drug-eluting biomatrices for reconstructive surgery.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 13, 2026Robust Pipeline of Innovative Core Products from Our Proven Research and Development Capabilities. We have brought to market two commercial…View ↗
Sales channel
The earlier report described a mix of a direct sales force, commercial partners and independent sales agents. The latest report says its commercial products are sold through independent sales agents.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 13, 2026Our go-to-market strategy includes a hybrid of a direct sales force, commercial partners and independent sales agents. As of December 31…View ↗
Both SimpliDerm and our Cardiovascular products are sold through independent sales agents. In March 2023, we entered into a non-exclusive…View ↗
Competes with Gore, Terumo, AbbVie, MTF, Stryker, Evergen, and Integra
10-K for FY2025, filed Mar 13, 2026Our products compete primarily with other cardiovascular repair and human-derived acellular dermis products. ProxiCor, Tyke and VasCure…View ↗
Loading...